AHK-Cu

AHK-Cu (L-Alanyl-L-Histidyl-L-Lysine copper(II)) is a synthetic copper-binding tripeptide in which the glycine residue of the well-characterized plasma tripeptide GHK is replaced with alanine, giving the sequence Ala-His-Lys. Like GHK, the AHK sequence contains the histidine imidazole nitrogen and the terminal amine/lysine groups that together form a high-affinity chelation site for divalent copper (Cu²⁺), producing a stable, biologically active peptide-copper complex (molecular formula C15H25CuN6O4, molecular weight approximately 416.9 g/mol, CAS 682809-81-0). In cosmetic ingredient nomenclature the complex is listed as a copper tripeptide and is closely related to the copper tripeptide family used in topical skin and scalp formulations.

The scientific interest in copper tripeptides stems from the fact that copper is an obligatory cofactor for several enzymes central to connective tissue biology, including lysyl oxidase (collagen and elastin cross-linking), superoxide dismutase (antioxidant defense), tyrosinase (pigment synthesis), and cytochrome c oxidase (mitochondrial respiration). Free copper ions are reactive and poorly tolerated by tissue, so peptide chelation provides a means of delivering copper in a controlled, buffered, and biologically usable form. AHK-Cu is studied as one such carrier system.

Where GHK-Cu is most extensively documented for dermal matrix remodeling and wound repair, the published research on AHK-Cu is concentrated on the hair follicle. The most frequently cited study, an in vitro investigation by Pyo and colleagues published in Archives of Pharmacal Research in 2007, examined the tripeptide-copper complex AHK-Cu in cultured human dermal papilla cells and in cultured human hair follicles, reporting increased dermal papilla cell proliferation, elevated vascular endothelial growth factor (VEGF) production, and prolongation of the anagen (growth) phase in organ-cultured follicles relative to untreated controls.

AHK-Cu is supplied here as a lyophilized (freeze-dried) powder at greater than 98% purity by HPLC, in a 100 mg research vial. The blue-to-violet color characteristic of reconstituted copper peptide solutions reflects the coordinated Cu²⁺ center. This material is sold strictly for in vitro laboratory and research use only and is not a drug, cosmetic, dietary supplement, or medical device. It is not for human or veterinary consumption or administration.

AHK-Cu is best understood as a copper-delivery and copper-signaling molecule rather than a receptor-targeted peptide drug. Its documented and proposed mechanisms follow from three properties: high-affinity copper chelation, small molecular size, and structural similarity to endogenous matrix-regulating tripeptides.

Copper Chelation and Enzyme Cofactor Supply

The imidazole nitrogen of histidine together with the peptide backbone nitrogen and terminal amino group form a square-planar coordination environment that binds Cu²⁺ with high stability. This buffered copper can be exchanged with copper-dependent enzymes and copper-transport proteins. The most relevant enzyme for connective tissue and follicular research is lysyl oxidase, which requires copper to catalyze the oxidative deamination of lysine residues that produces covalent cross-links in collagen and elastin fibers. Copper is likewise required by Cu/Zn superoxide dismutase, an enzyme that converts superoxide radicals to hydrogen peroxide and therefore contributes to oxidative stress defense in dermal and follicular tissue.

Dermal Papilla Cell Proliferation

The dermal papilla is the mesenchymal signaling center at the base of the hair follicle that governs follicle size, anagen duration, and the hair cycle. In the 2007 Archives of Pharmacal Research study, AHK-Cu increased proliferation of cultured human dermal papilla cells in a concentration-dependent manner. Because dermal papilla cell number and activity are tightly correlated with anagen maintenance and hair shaft caliber in experimental systems, this proliferative effect is the primary mechanistic observation invoked in follicular research on the compound.

VEGF Upregulation and Perifollicular Angiogenesis

The same study reported that AHK-Cu treatment increased VEGF protein output from dermal papilla cells. VEGF is the principal driver of perifollicular capillary expansion; independent follicular biology work has established that VEGF-mediated vascularization of the follicular papilla supports larger follicles and faster hair shaft growth in murine models. Copper ions are also known to stabilize hypoxia-inducible factor-driven angiogenic signaling, providing a plausible metal-dependent route to the same endpoint.

Anagen Prolongation in Follicle Organ Culture

In the organ-culture arm of the 2007 work, human hair follicles maintained ex vivo showed extended anagen and greater hair shaft elongation under AHK-Cu treatment than controls. Anagen prolongation, rather than de novo follicle formation, is the mechanism generally proposed for copper tripeptides in hair research.

Extracellular Matrix and Collagen Synthesis

Copper tripeptides as a class have been reported to stimulate fibroblast synthesis of collagen (particularly types I and III), glycosaminoglycans, and the small proteoglycan decorin, and to modulate matrix metalloproteinase activity so that degraded matrix is replaced rather than simply removed. For AHK-Cu specifically, the collagen and basement-membrane findings are largely extrapolated from the broader copper tripeptide literature and from cosmetic-industry testing rather than from a large independent primary-literature base, and should be treated as preliminary.

Comparison with GHK-Cu

The single glycine-to-alanine substitution adds a methyl group at the first residue. This changes hydrophobicity and steric presentation without disrupting the histidine-based copper site, so copper affinity is retained. AHK-Cu should not be assumed to reproduce GHK-Cu's much larger gene-expression dataset; the two are structurally analogous but separately characterized compounds, and AHK-Cu's evidence base is smaller and more narrowly focused on the follicle.

The AHK-Cu literature is substantially smaller than the GHK-Cu literature. It consists of a small number of in vitro and organ-culture studies, supporting evidence from the broader copper-peptide and copper-biology fields, and cosmetic-industry evaluation data. There are no large randomized controlled human trials of AHK-Cu, and no clinical endpoints have been established.

Primary In Vitro Study: Human Hair Growth (2007)

Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. "The effect of tripeptide-copper complex on human hair growth in vitro." Archives of Pharmacal Research, 2007;30(7):834-839. Working with cultured human dermal papilla cells and organ-cultured human hair follicles obtained from surgical specimens, the investigators reported that the tripeptide-copper complex AHK-Cu stimulated dermal papilla cell proliferation, increased VEGF expression, and prolonged anagen with greater hair shaft elongation in follicle culture compared with untreated controls. This remains the most direct experimental support for follicular applications of AHK-Cu and is the study cited most often by formulators and researchers.

Copper Biology and Enzyme Cofactor Evidence

The mechanistic plausibility of copper tripeptides rests on well-established copper biochemistry. Lysyl oxidase is a copper-dependent amine oxidase required for the covalent cross-linking that gives collagen and elastin their tensile strength; copper deficiency produces demonstrable connective tissue fragility, impaired wound strength, and hair and pigment abnormalities in both animal models and human copper-deficiency states such as Menkes disease. This body of work is not AHK-Cu-specific but explains why controlled copper delivery is investigated as a matrix and follicular intervention.

Copper Tripeptide Class Evidence (GHK-Cu Comparator Data)

The closely related tripeptide GHK-Cu has been studied for more than five decades and provides the class-level context for AHK-Cu research. Pickart and Margolina's 2018 review in the International Journal of Molecular Sciences summarizes gene-expression, wound healing, matrix synthesis, antioxidant, and anti-inflammatory findings for GHK-Cu, including microarray data indicating that copper tripeptide exposure shifts fibroblast transcriptional profiles associated with matrix production and repair. These findings are frequently used to frame hypotheses about AHK-Cu but do not substitute for direct AHK-Cu evidence.

Percutaneous Copper Delivery

Work by Hostynek and Maibach on copper penetration through human skin established that copper flux across the stratum corneum is measurable but low, and is influenced strongly by the chemical species and vehicle in which copper is presented. This literature is the basis for the argument that chelated peptide-copper complexes are better suited to topical research models than inorganic copper salts, and it also underpins the observation that systemic copper loading from topical copper peptide use is minimal.

Cosmetic Formulation Experience

Copper tripeptides including AHK-Cu appear as active ingredients in topical scalp serums, post-procedure skin formulations, and anti-aging cosmetic products. Accumulated formulation experience indicates good physical compatibility in aqueous systems at mildly acidic to neutral pH and general tolerability at the low concentrations typical of cosmetics. However, cosmetic use data are observational, are not blinded or controlled, and cannot establish efficacy.

Evidence Gaps and Limitations

Researchers evaluating AHK-Cu should note the following limitations: the follicular findings derive from in vitro and ex vivo systems rather than in vivo dosing; no pharmacokinetic profile, half-life, or bioavailability data for AHK-Cu have been established in the peer-reviewed literature; comparative head-to-head studies against GHK-Cu, minoxidil, or other follicular agents are absent; and independent replication of the 2007 in vitro results is limited. Peptide-copper complexes are also sensitive to oxidation, chelating excipients, and strongly alkaline conditions, which complicates cross-study comparison of formulations. Claims that extend AHK-Cu findings to human outcomes are not supported by the current evidence base.

AHK-Cu has no established human safety profile from controlled clinical trials, and this product is supplied strictly for in vitro laboratory research use only - it is not for human or animal administration. What is known about tolerability comes from three indirect sources: cosmetic-industry use of copper tripeptides in topical formulations, the much larger safety record of the structurally analogous tripeptide GHK-Cu, and general copper toxicology.

Topical copper tripeptide formulations used at cosmetic concentrations have generally been well tolerated in reported use, with adverse events limited mainly to mild, transient local effects such as redness, tingling, dryness, or irritation that resolve on discontinuation; true allergic contact sensitization to copper peptides is uncommon but has been described for copper-containing preparations.

The principal theoretical hazard for any copper complex is copper overload. Copper is an essential trace element with a narrow therapeutic window: excessive systemic copper can cause gastrointestinal distress, hepatic injury, and hemolysis, and chronic accumulation is the pathologic mechanism of Wilson's disease.

Studies of copper penetration through human skin indicate that percutaneous flux from chelated copper preparations is low, and no cases of systemic copper toxicity attributable to topical copper peptide cosmetics have been documented; nevertheless, any research protocol involving repeated, high-concentration, occluded, or non-topical exposure must account for cumulative copper load.

Individuals or models with Wilson's disease, other copper-handling disorders, or hepatic impairment represent an explicit contraindication category in any copper-delivery research design.

Peptide-copper complexes are chemically reactive systems: copper can catalyze Fenton-type oxidative chemistry when it is not properly chelated, so degraded, oxidized, improperly reconstituted, or discolored material may behave very differently from intact complex and should be discarded rather than used. AHK-Cu is incompatible with strong chelators, reducing agents, high-pH buffers, and vitamin C formulations, which can strip or reduce the copper center.

No pharmacokinetic, reproductive toxicity, genotoxicity, carcinogenicity, or drug-interaction data exist for AHK-Cu specifically, so no safety assurance can be offered for pregnancy, lactation, pediatric contexts, or concomitant compound use.

Handle as a laboratory chemical: use gloves and eye protection, avoid inhalation of the lyophilized powder, reconstitute with appropriate sterile diluent, protect from light and heat, store the sealed vial refrigerated (2-8 degrees C) or frozen for long-term storage, and refrigerate reconstituted solution with limited shelf life.

Because the evidence base is preclinical and narrow, any statement about human efficacy or human safety for AHK-Cu is unsupported by current published research.